Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 2009;119:53-61
Published online before print December 22, 2008, doi: 10.1161/CIRCULATIONAHA.108.785915
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
119/1/53    most recent
CIRCULATIONAHA.108.785915v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Williams, B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Williams, B.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*ATORVASTATIN
*HEPTANOIC ACID
*PYRROLE
Medline Plus Health Information
*High Blood Pressure
*Statins
Related Collections
Right arrow Lipids
Right arrow Pathophysiology
Right arrow Clinical Studies
Right arrow Other Treatment
Right arrowRelated Article

(Circulation. 2009;119:53-61.)
© 2009 American Heart Association, Inc.


Hypertension

Impact of Statin Therapy on Central Aortic Pressures and Hemodynamics

Principal Results of the Conduit Artery Function Evaluation–Lipid-Lowering Arm (CAFE-LLA) Study

Bryan Williams, MD, FRCP; Peter S. Lacy, PhD; J. Kennedy Cruickshank, MD, FRCP; David Collier, MBBS, PhD; Alun D. Hughes, MBBS, PhD; Alice Stanton, PhD, FRCPI; Simon Thom, MD, FRCP; Herbert Thurston, MD, FRCP, for the CAFE and ASCOT Investigators

From the Department of Cardiovascular Sciences, University of Leicester, Leicester, UK (B.W., P.S.L., H.T.); University Department of Medicine, Manchester Royal Infirmary, Manchester, UK (J.K.C.); Barts and the London, Queen Mary’s School of Medicine, London, UK (D.C.); International Centre for Circulatory Health, Imperial College, London, UK (A.D.H., S.T.); and Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland (A.S.).

Correspondence to Bryan Williams, MD, FRCP, FAHA, Department of Cardiovascular Sciences, University of Leicester, Clinical Sciences Building, Leicester Royal Infirmary, Leicester, LE2 7LX, UK. E-mail bw17{at}le.ac.uk

Received April 15, 2008; accepted September 30, 2008.

Background— Statins reduce the risk of cardiovascular events in people with hypertension. This benefit could arise from a beneficial effect of statins on central aortic pressures and hemodynamics. The Conduit Artery Function Evaluation–Lipid-Lowering Arm (CAFE-LLA) study, an Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) substudy, investigated this hypothesis in a prospective placebo-controlled study of treated patients with hypertension.

Methods and Results— CAFE-LLA recruited 891 patients randomized to atorvastatin 10 mg/d or placebo from 5 centers in the United Kingdom and Ireland. Radial artery applanation tonometry and pulse-wave analysis were used to derive central aortic pressures and hemodynamic indices at repeated visits over 3.5 years of follow-up. Atorvastatin lowered low-density lipoprotein cholesterol by 32.4 mg/dL (95% confidence interval [CI], 28.6 to 36.3) and total cholesterol by 35.1 mg/dL (95% confidence interval, 30.9 to 39.4) relative to placebo. Time-averaged brachial blood pressure was similar in CAFE-LLA patients randomized to atorvastatin or placebo (change in brachial systolic blood pressure, –0.1 mm Hg [95% CI, –1.8 to 1.6], P=0.9; change in brachial pulse pressure, –0.02 mm Hg [95% CI, –1.6 to 1.6], P=0.9). Atorvastatin did not influence central aortic pressures (change in aortic systolic blood pressure, –0.5 mm Hg [95% CI, –2.3 to 1.2], P=0.5; change in aortic pulse pressure, –0.4 mm Hg [95% CI, –1.9 to 1.0], P=0.6) and had no influence on augmentation index (change in augmentation index, –0.4%; 95% CI, –1.7 to 0.8; P=0.5) or heart rate (change in heart rate, 0.25 bpm; 95% CI, –1.3 to 1.8; P=0.7) compared with placebo. The effect of statin or placebo therapy was not modified by the blood pressure–lowering treatment strategy in the factorial design.

Conclusions— Statin therapy sufficient to significantly reduce cardiovascular events in treated hypertensive patients in ASCOT did not influence central aortic blood pressure or hemodynamics in a large representative cohort of ASCOT patients in CAFE-LLA.


 

CLINICAL PERSPECTIVE


Related Article:

Clinical Summaries
Circulation 2009 119: 1-4. [Extract] [Full Text]



This article has been cited by other articles:


Home page
HypertensionHome page
J. D. Cameron
Wave Intensity Analysis and Central Blood Pressure
Hypertension, November 1, 2009; 54(5): 958 - 959.
[Full Text] [PDF]


Home page
HypertensionHome page
C. Manisty, J. Mayet, R. J. Tapp, P. S. Sever, N. Poulter, S. A. McG. Thom, A. D. Hughes, and on behalf of the ASCOT Investigators
Atorvastatin Treatment Is Associated With Less Augmentation of the Carotid Pressure Waveform in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT)
Hypertension, November 1, 2009; 54(5): 1009 - 1013.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
J. S. Orr, A. L. Dengo, J. M. Rivero, and K. P. Davy
Arterial Destiffening With Atorvastatin in Overweight and Obese Middle-Aged and Older Adults
Hypertension, October 1, 2009; 54(4): 763 - 768.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
A. P. Avolio, L. M. Van Bortel, P. Boutouyrie, J. R. Cockcroft, C. M. McEniery, A. D. Protogerou, M. J. Roman, M. E. Safar, P. Segers, and H. Smulyan
Role of Pulse Pressure Amplification in Arterial Hypertension: Experts' Opinion and Review of the Data
Hypertension, August 1, 2009; 54(2): 375 - 383.
[Full Text] [PDF]


Home page
HypertensionHome page
K. K. Koh
Combination Treatment to Prevent Atherosclerosis
Hypertension, July 1, 2009; 54(1): e10 - e10.
[Full Text] [PDF]


Home page
HypertensionHome page
T. Kushiro
Response to Combination Treatment to Prevent Atherosclerosis
Hypertension, July 1, 2009; 54(1): e11 - e11.
[Full Text] [PDF]


Home page
HypertensionHome page
J. K. Cruickshank, M. Rezailashkajani, and G. Goudot
Arterial Stiffness, Fatness, and Physical Fitness: Ready for Intervention in Childhood and Across the Life Course?
Hypertension, April 1, 2009; 53(4): 602 - 604.
[Full Text] [PDF]